Literature DB >> 8023850

Canavan disease: mutations among Jewish and non-Jewish patients.

R Kaul1, G P Gao, M Aloya, K Balamurugan, A Petrosky, K Michals, R Matalon.   

Abstract

Canavan disease is an autosomal recessive leukodystrophy caused by the deficiency of aspartoacylase (ASPA). Sixty-four probands were analyzed for mutations in the ASPA gene. Three point mutations--693C-->A, 854A-->C, and 914C-->A--were identified in the coding sequence. The 693C-->A and 914C-->A base changes, resulting in nonsense tyr231-->ter and missense ala305-->glu mutations, respectively, lead to complete loss of ASPA activity in in vitro expression studies. The 854A-->C transversion converted glu to ala in codon 285. The glu285-->ala mutant ASPA has 2.5% of the activity expressed by the wild-type enzyme. A fourth mutation, 433 --2(A-->G) transition, was identified at the splice-acceptor site in intron 2. The splice-site mutation would lead to skipping of exon 3, accompanied by a frameshift, and thus would produce aberrant ASPA. Of the 128 unrelated Canavan chromosomes analyzed, 88 were from probands of Ashkenazi Jewish descent. The glu285-->ala mutation was predominant (82.9%) in this population, followed by the tyr231-->ter (14.8%) and 433 --2(A-->G) (1.1%) mutations. The three mutations account for 98.8% of the Canavan chromosomes of Ashkenazi Jewish origin. The ala305-->glu mutation was found exclusively in non-Jewish probands of European descent and constituted 60% of the 40 mutant chromosomes. Predominant occurrence of certain mutations among Ashkenazi Jewish and non-Jewish patients with Canavan disease would suggest a founding-father effect in propagation of these mutant chromosomes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8023850      PMCID: PMC1918221     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  18 in total

1.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

2.  Specificity of amino acid acylases.

Authors:  S M BIRNBAUM; L LEVINTOW; R B KINGSLEY; J P GREENSTEIN
Journal:  J Biol Chem       Date:  1952-01       Impact factor: 5.157

3.  Cerebral spongy degeneration of infancy. A biochemical and ultrastructural study of affected twins.

Authors:  B T Adornato; J S O'Brien; P W Lampert; T F Roe; H B Neustein
Journal:  Neurology       Date:  1972-02       Impact factor: 9.910

4.  Frequency of three Hex A mutant alleles among Jewish and non-Jewish carriers identified in a Tay-Sachs screening program.

Authors:  B H Paw; P T Tieu; M M Kaback; J Lim; E F Neufeld
Journal:  Am J Hum Genet       Date:  1990-10       Impact factor: 11.025

5.  Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease.

Authors:  R Matalon; K Michals; D Sebesta; M Deanching; P Gashkoff; J Casanova
Journal:  Am J Med Genet       Date:  1988-02

6.  SSIEM Award. Aspartoacylase deficiency: the enzyme defect in Canavan disease.

Authors:  R Matalon; R Kaul; J Casanova; K Michals; A Johnson; I Rapin; P Gashkoff; M Deanching
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

7.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

8.  Aspartoacylase deficiency and Canavan disease in Saudi Arabia.

Authors:  P T Ozand; G G Gascon; M Dhalla
Journal:  Am J Med Genet       Date:  1990-02

9.  Spongy degeneration of the brain in Israel: a retrospective study.

Authors:  M Ungar; R M Goodman
Journal:  Clin Genet       Date:  1983-01       Impact factor: 4.438

Review 10.  Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan's disease). A review.

Authors:  M Adachi; L Schneck; J Cara; B W Volk
Journal:  Hum Pathol       Date:  1973-09       Impact factor: 3.466

View more
  34 in total

1.  The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients.

Authors:  O N Elpeleg; A Shaag
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

Review 2.  Biochemistry and molecular biology of Canavan disease.

Authors:  R Matalon; K Michals-Matalon
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

3.  Comprehensive arrayed primer extension array for the detection of 59 sequence variants in 15 conditions prevalent among the (Ashkenazi) Jewish population.

Authors:  Iris Schrijver; Maigi Külm; Phyllis I Gardner; Eugene P Pergament; Morris B Fiddler
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

4.  Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease.

Authors:  R Kaul; G P Gao; R Matalon; M Aloya; Q Su; M Jin; A B Johnson; R B Schutgens; J T Clarke
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

Review 5.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

6.  Development of genomic DNA reference materials for genetic testing of disorders common in people of ashkenazi jewish descent.

Authors:  Lisa Kalman; Jean Amos Wilson; Arlene Buller; John Dixon; Lisa Edelmann; Louis Geller; William Edward Highsmith; Leonard Holtegaard; Ruth Kornreich; Elizabeth M Rohlfs; Toby L Payeur; Tina Sellers; Lorraine Toji; Kasinathan Muralidharan
Journal:  J Mol Diagn       Date:  2009-10-08       Impact factor: 5.568

7.  Anal anomalies: an uncommon feature of velocardiofacial (Shprintzen) syndrome?

Authors:  S Worthington; A Colley; K Fagan; K Dai; A H Lipson
Journal:  J Med Genet       Date:  1997-01       Impact factor: 6.318

8.  Relationship between enzyme properties and disease progression in Canavan disease.

Authors:  Stephen Zano; Yasanandana S Wijayasinghe; Radhika Malik; Joshua Smith; Ronald E Viola
Journal:  J Inherit Metab Dis       Date:  2012-08-01       Impact factor: 4.982

9.  Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.

Authors:  Jiho Sohn; Peter Bannerman; Fuzheng Guo; Travis Burns; Laird Miers; Christopher Croteau; Naveen K Singhal; Jennifer A McDonough; David Pleasure
Journal:  J Neurosci       Date:  2017-01-11       Impact factor: 6.167

10.  Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease.

Authors:  Jeremy S Francis; Vladimir Markov; Paola Leone
Journal:  J Inherit Metab Dis       Date:  2013-11-28       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.